In addition to the use of imatinib in GIST, targeted therapeutic drugs, the antiangiogenic agents anlotinib (Wang et al., 2019a), cabozantinib (Wang et al., 2021), and pazopanib (Shiozawa et al., 2018), and the epidermal growth factor receptor (EGFR) inhibitor erlotinib (Wang et al., 2019b) have also been used as rescue drugs after chemotherapy failure in OS. Here, EGFR is linked to gastrointestinal stromal tumor.